COLLEGIUM PHARMACEUTICAL, INC - 8-K Filing

Collegium Pharmaceutical reports record Q3 2026 net revenues of $216.3 million and reaffirms full-year guidance. (Items: 2.02 Results of Operations and Financial Condition, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $COLL

Read the full article at SEC EDGAR

More Regulatory news